West Pharmaceutical Services Inc (WST) KPIs and segments
Close on Nov 18, 2026Market cap $28.14BP/E 45.3Yield 0.21%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của West Pharmaceutical Services · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của West Pharmaceutical Services: 59 chỉ số vận hành, trong đó có Consolidated Net Sales, Proprietary Products Segment Net Sales và West Vantage Segment Net Sales, lấy từ 219 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Proprietary Products($M) | 729 | 723 | 694 | 662 | 648 | 620 | 563 | 614 | 601 | 560 | 560 | 594 | |
West Vantage($M) | 146 | 150 | 151 | 157 | 147 | 135 | |||||||
Contract-Manufactured Products($M) | 143 | 157 | 147 | 135 | 135 | 146 | 142 | 136 | 138 | ||||
Proprietary Products($M) | 231 | 212 | 189 | 190 | 175 | 162 | 131 | 162 | 158 | 131 | 126 | 164 | |
West Vantage($M) | 15.5 | 12.9 | 15.6 | 22.3 | 17.8 | 13.5 | |||||||
Contract-Manufactured Products($M) | 9.80 | 22.3 | 17.8 | 13.5 | 16.2 | 21.8 | 17.2 | 17.1 | 18.8 | ||||
Proprietary Products($M) | 323 | 308 | 273 | 286 | 264 | 248 | 210 | 251 | 236 | 207 | 207 | ||
West Vantage($M) | 24 | 21.2 | 23.3 | 30.3 | 25.6 | 21.7 | |||||||
Contract-Manufactured Products($M) | 18.2 | 30.3 | 25.6 | 21.7 | 22.9 | 29 | 23 | 23.1 | |||||
West Vantage($M) | -8.20 | -5.10 | -5.60 | -13.6 | -25.5 | -18.1 | |||||||
Contract-Manufactured Products($M) | -18.3 | -13.6 | -25.5 | -18.1 | -24.2 | -30 | -39.2 | -27.6 | |||||
Proprietary Products($M) | -28.6 | -35.4 | -36.5 | -56.2 | -47.7 | -48.5 | -51.9 | -79.1 | -47.8 | -58.5 | -61.1 | ||
Proprietary Products($M) | 2,925 | 2,909 | 2,932 | 2,987 | 2,989 | 2,829 | 2,625 | 2,621 | 2,629 | ||||
Contract-Manufactured Products($M) | 718 | 686 | 668 | 628 | 612 | 528 | |||||||
West Vantage($M) | 697 | 718 | 740 | 718 | |||||||||
Consolidated Net Sales($M)7 | 875 | 872 | 845 | 805 | 805 | 767 | 698 | 749 | 747 | 702 | 695 | 732 | |
Consolidated Organic Net Sales Growth (Constant Currency & Ex-Divestitures)(%) | 11.9% | 12.7% | 15.3% | 3.3% | 5.0% | 6.8% | 2.1% | 3.3% | -0.5% | -5.9% | -3.0% | 1.4% | |
Consolidated Reported Net Sales Growth (YoY)(%) | 8.7% | 13.8% | 21.0% | 7.5% | 7.7% | 9.2% | 0.4% | 2.3% | -0.1% | -6.9% | -3.0% | 3.3% | |
Consolidated Organic Net Sales (Non-GAAP Constant Currency)($M) | 867 | 775 | 750 | 710 | 756 | 744 | 708 | 692 | 714 | ||||
Consolidated Foreign Currency Translation Impact($M) | -4 | 16.5 | -11.7 | -7.20 | 2.90 | -6.10 | 3.40 | 18.5 | |||||
Consolidated Foreign Currency Translation Impact (YoY %)(%) | 1.1% | 5.7% | 4.2% | 2.7% | |||||||||
Quarterly Consolidated Revenue Bridge: Volume and Mix Contribution($M) | 58.3 | 67 | 82.7 | 38 | 44.1 | ||||||||
Quarterly Consolidated Revenue Bridge: Sales Price Contribution($M) | 33.6 | 30.3 | 24.2 | 11.7 | 12.5 | ||||||||
Proprietary Products Segment Net Sales($M)10 | 729 | 723 | 694 | 662 | 648 | 620 | 563 | 614 | 601 | 560 | 560 | 594 | |
Proprietary Products Organic Net Sales Growth(%) | 16.6% | 15.5% | 17.5% | 3.6% | 5.1% | 8.4% | 2.4% | 4.5% | -0.5% | -8.4% | -4.0% | -0.3% | |
Proprietary Products Reported Net Sales Growth(%) | 12.6% | 16.6% | 23.3% | 7.8% | 7.7% | 10.7% | 0.6% | -0.2% | -9.4% | -4.0% | 1.5% | ||
Proprietary Products Organic Net Sales (Non-GAAP Constant Currency)($M) | 720 | 618 | 607 | 573 | 620 | 599 | 565 | 557 | 578 | ||||
Proprietary Products Foreign Currency Translation Impact($M) | -3 | 12.9 | -9.70 | -6.50 | 2.20 | -5.40 | 2.80 | 15.7 | |||||
Proprietary Products Foreign Currency Translation Impact (YoY %)(%) | 1.1% | 5.8% | 4.2% | 2.6% | |||||||||
Proprietary Products Share of Consolidated Net Sales(%) | 83.0% | 82.0% | 82.0% | 80.0% | |||||||||
High-Value Products (HVP) Share of Proprietary Products Segment Sales (Legacy Disclosure)(%) | 74.0% | 72.0% | 75.0% | ||||||||||
High-Value Product (HVP) Components Net Sales($M)4 | 467 | 424 | 409 | 390 | 390 | 355 | 316 | 324 | 335 | ||||
HVP Components Share of Consolidated Net Sales(%) | 53.0% | 49.0% | 48.0% | 48.0% | 48.0% | 47.0% | 45.0% | 45.0% | 46.0% | 47.0% | |||
HVP Components Organic Net Sales Growth(%) | 20.3% | 18.4% | 22.6% | 15.1% | 13.3% | ||||||||
HVP Components Reported Net Sales Growth(%) | 19.7% | 19.4% | 29.6% | 20.3% | 16.3% | ||||||||
HVP Components Foreign Currency Impact (YoY %)(%) | 1.0% | 7.0% | 5.2% | 3.0% | |||||||||
High-Value Product (HVP) Delivery Devices Net Sales($M)4 | 99.1 | 131 | 124 | 110 | 99.1 | 101 | 95.8 | 133 | 118 | ||||
HVP Delivery Devices Share of Consolidated Net Sales(%) | 11.0% | 15.0% | 15.0% | 12.0% | 13.0% | 14.0% | 20.0% | 23.0% | 22.0% | ||||
HVP Delivery Devices Organic Net Sales Growth(%) | 26.4% | 29.2% | 27.5% | -18.1% | -16.7% | ||||||||
HVP Delivery Devices Reported Net Sales Growth(%) | 0.0% | 29.6% | 29.0% | -16.9% | -15.7% | ||||||||
HVP Delivery Devices Foreign Currency Impact (YoY %)(%) | 0.4% | 1.5% | 1.2% | 1.0% | |||||||||
Standard Packaging Net Sales($M)4 | 163 | 167 | 161 | 162 | 158 | 163 | 151 | 157 | 149 | ||||
Standard Packaging Share of Consolidated Net Sales(%) | 19.0% | 19.0% | 19.0% | 20.0% | 21.0% | 22.0% | 16.0% | 11.0% | 11.0% | ||||
Standard Packaging Organic Net Sales Growth(%) | 3.1% | 0.7% | 0.5% | -1.7% | 3.6% | ||||||||
Standard Packaging Reported Net Sales Growth(%) | 2.9% | 2.4% | 6.7% | 3.0% | 6.7% | ||||||||
Standard Packaging Foreign Currency Impact (YoY %)(%) | 1.7% | 6.2% | 4.7% | 3.1% | |||||||||
West Vantage (Contract-Manufactured Products) Segment Net Sales($M)6 | 146 | 150 | 151 | 143 | 157 | 147 | 135 | 135 | 146 | 142 | 136 | 138 | |
West Vantage Share of Consolidated Net Sales(%) | 17.0% | 17.0% | 18.0% | 20.0% | 19.0% | 19.0% | 19.0% | 20.0% | 20.0% | ||||
West Vantage Organic Net Sales Growth(%) | -6.6% | 0.8% | 6.2% | 1.9% | 4.9% | 0.5% | 0.8% | -2.0% | 0.0% | 5.4% | 1.3% | 9.4% | |
West Vantage Reported Net Sales Growth(%) | -7.3% | 2.0% | 11.6% | 6.2% | 8.0% | 3.0% | -0.7% | -2.5% | 4.9% | 1.8% | 11.6% | ||
West Vantage Organic Net Sales (Non-GAAP Constant Currency)($M) | 147 | 157 | 143 | 137 | 136 | 145 | 143 | 135 | 136 | ||||
West Vantage Foreign Currency Translation Impact($M) | -1 | 3.60 | -2 | -0.70 | 0.70 | -0.70 | 0.60 | 2.80 | |||||
West Vantage Foreign Currency Translation Impact (YoY %)(%) | 1.2% | 5.4% | 4.3% | 3.1% | |||||||||
GLP-1 Franchise Share of Consolidated Net Sales(%)2 | 21.0% | 18.0% | 18.0% | 17.0% | 17.0% | ||||||||
GLP-1 Elastomers (Proprietary Products) Share of Consolidated Net Sales(%) | 12.0% | 10.0% | 10.0% | 10.0% | 9.0% | 8.0% | |||||||
GLP-1 Contract Manufacturing (West Vantage) Share of Consolidated Net Sales(%) | 9.0% | 8.0% | 8.0% | 7.0% | 8.0% | ||||||||
Ongoing EU GMP Annex 1 / HVP Customer Upgrade Projects | 325 | 375 | 370 | 340 | |||||||||
Biologics Market Unit Net Sales (Proprietary Products)($M)4 | 379 | 375 | 355 | 340 | 329 | 288 | 269 | 305 | 296 | ||||
Biologics Share of Consolidated Net Sales(%) | 43.0% | 43.0% | 42.0% | 42.0% | 41.0% | 38.0% | 39.0% | 40.0% | 36.0% | 37.0% | |||
Biologics Organic Net Sales Growth(%) | 23.2% | 29.2% | 25.9% | 7.3% | 8.3% | ||||||||
Biologics Reported Net Sales Growth(%) | 15.3% | 30.3% | 31.6% | 11.5% | 11.0% | ||||||||
Biologics Foreign Currency Impact (YoY %)(%) | 1.1% | 5.7% | 4.2% | 2.7% | |||||||||
Pharma Market Unit Net Sales (Proprietary Products)($M)4 | 221 | 205 | 211 | 192 | 183 | 199 | 181 | 182 | 174 | ||||
Pharma Share of Consolidated Net Sales(%) | 25.0% | 24.0% | 25.0% | 24.0% | 22.0% | 26.0% | 26.0% | 23.0% | 26.0% | 25.0% | |||
Pharma Organic Net Sales Growth(%) | 21.4% | 1.6% | 9.8% | 0.3% | 1.4% | ||||||||
Pharma Reported Net Sales Growth(%) | 21.3% | 3.3% | 16.6% | 5.5% | 4.7% | ||||||||
Pharma Foreign Currency Impact (YoY %)(%) | 1.7% | 6.8% | 5.2% | 3.3% | |||||||||
Generics Market Unit Net Sales (Proprietary Products)($M)4 | 128 | 143 | 129 | 130 | 136 | 134 | 113 | 127 | 131 | ||||
Generics Share of Consolidated Net Sales(%) | 15.0% | 16.0% | 15.0% | 17.0% | 17.0% | 16.0% | 18.0% | 18.0% | 18.0% | ||||
Generics Organic Net Sales Growth(%) | -4.5% | 6.7% | 9.8% | -0.6% | 2.6% | ||||||||
Generics Reported Net Sales Growth(%) | -5.7% | 6.9% | 14.2% | 2.2% | 4.0% | ||||||||
Generics Foreign Currency Impact (YoY %)(%) | 0.2% | 4.4% | 2.8% | 1.4% | |||||||||
Americas Net Sales($M)4 | 401 | 389 | 377 | 359 | 375 | 350 | 339 | 355 | 357 | ||||
Americas Share of Consolidated Net Sales(%) | 46.0% | 44.0% | 45.0% | 45.0% | 47.0% | 45.0% | 49.0% | 48.0% | 43.0% | 43.0% | |||
Americas Organic Net Sales Growth(%) | 12.4% | 10.6% | 10.8% | 0.7% | 5.2% | ||||||||
Americas Reported Net Sales Growth(%) | 6.9% | 11.2% | 11.3% | 1.1% | 5.3% | ||||||||
Americas Foreign Currency Impact (YoY %)(%) | 0.6% | 0.5% | 0.4% | 0.1% | |||||||||
Europe, Middle East & Africa (EMEA) Net Sales($M)4 | 376 | 400 | 399 | 370 | 361 | 350 | 307 | 323 | 330 | ||||
EMEA Share of Consolidated Net Sales(%) | 43.0% | 46.0% | 47.0% | 46.0% | 45.0% | 46.0% | 44.0% | 44.0% | 48.0% | 48.0% | |||
EMEA Organic Net Sales Growth(%) | 5.7% | 12.1% | 17.9% | 5.1% | 3.1% | ||||||||
EMEA Reported Net Sales Growth(%) | 4.2% | 14.3% | 30.1% | 14.6% | 9.4% | ||||||||
EMEA Foreign Currency Impact (YoY %)(%) | 2.2% | 12.2% | 9.5% | 6.3% | |||||||||
Asia Pacific Net Sales($M)4 | 97.1 | 83.8 | 68.2 | 76.2 | 68.2 | 67.1 | 52.2 | 71 | 60.3 | ||||
Asia Pacific Share of Consolidated Net Sales(%) | 11.0% | 10.0% | 8.0% | 8.0% | 9.0% | 7.0% | 8.0% | 9.0% | 9.0% | ||||
Asia Pacific Organic Net Sales Growth(%) | 41.9% | 27.0% | 29.3% | 8.3% | 14.9% | ||||||||
Asia Pacific Reported Net Sales Growth(%) | 42.4% | 24.9% | 30.7% | 7.3% | 13.1% | ||||||||
Asia Pacific Foreign Currency Impact (YoY %)(%) | -2.1% | 1.4% | -1.0% | -1.8% | |||||||||
United States Net Sales1 | |||||||||||||
United States Long-Lived Assets($M) | 835 | 832 | 757 | ||||||||||
Germany Net Sales1 | |||||||||||||
Germany Long-Lived Assets($M) | 233 | 191 | 176 | ||||||||||
France Net Sales1 | |||||||||||||
France Long-Lived Assets($M) | 113 | 84.7 | 78.5 | ||||||||||
Ireland Net Sales1 | |||||||||||||
Ireland Long-Lived Assets($M) | 366 | 300 | 207 | ||||||||||
Other European Countries Net Sales1 | |||||||||||||
Other European Countries Long-Lived Assets($M) | 109 | 98.1 | 99.2 | ||||||||||
Other Countries Net Sales1 | |||||||||||||
Other Countries Long-Lived Assets($M) | 222 | 210 | 195 | ||||||||||
Proprietary Products Segment Gross Profit($M)2 | 323 | 308 | 273 | 286 | 264 | 248 | 210 | 251 | 236 | 207 | 207 | 253 | |
Proprietary Products Segment Gross Margin(%) | 44.4% | 42.6% | 39.3% | 43.2% | 40.8% | 40.1% | 37.3% | 40.8% | 39.2% | 37.0% | 37.0% | 42.7% | |
Proprietary Products Cost of Goods Sold (ASU 2023-07 Segment Expense)($M) | 405 | 415 | 421 | 376 | 384 | 372 | 353 | 363 | 366 | 353 | 352 | ||
Proprietary Products Segment Operating Profit($M)6 | 231 | 212 | 189 | 190 | 175 | 162 | 131 | 162 | 158 | 131 | 126 | 164 | |
Proprietary Products Segment Operating Margin(%) | 31.6% | 29.3% | 27.3% | 28.7% | 27.1% | ||||||||
Proprietary Products Research and Development Expense($M) | 18.3 | 19.7 | 15.8 | 21.8 | 17.1 | 19.1 | 16.3 | 18.5 | 15.5 | 17.5 | 17.6 | ||
Proprietary Products Selling, General and Administrative Expense($M) | 74.5 | 69.5 | 65 | 68.2 | 65.6 | 61.5 | 60.3 | 58.1 | 56.6 | 56.1 | 60.7 | ||
Proprietary Products Other Segment Expense (Income), Net($M) | 0 | 6.90 | 3.10 | 6 | 6.10 | 6 | 3 | 11.8 | 5.40 | 2.40 | 2.50 | ||
Proprietary Products Depreciation and Amortization($M) | 37.6 | 36.3 | 36.4 | 38.7 | 35.1 | 33.7 | 32.7 | 33.5 | 33.8 | 33 | 30 | ||
Proprietary Products Capital Expenditures($M) | 28.6 | 35.4 | 36.5 | 56.2 | 47.7 | 48.5 | 51.9 | 79.1 | 47.8 | 58.5 | 61.1 | ||
West Vantage Segment Gross Profit($M)2 | 24 | 21.2 | 23.3 | 18.2 | 30.3 | 25.6 | 21.7 | 22.9 | 29 | 23 | 23.1 | 24.7 | |
West Vantage Segment Gross Margin(%) | 16.5% | 14.2% | 15.5% | 12.7% | 19.3% | 17.5% | 16.1% | 17.0% | 19.9% | 16.2% | 17.0% | 17.9% | |
West Vantage Cost of Goods Sold (ASU 2023-07 Segment Expense)($M) | 122 | 129 | 127 | 125 | 127 | 121 | 113 | 112 | 117 | 119 | 113 | ||
West Vantage Segment Operating Profit($M)6 | 15.5 | 12.9 | 15.6 | 9.80 | 22.3 | 17.8 | 13.5 | 16.2 | 21.8 | 17.2 | 17.1 | 18.8 | |
West Vantage Segment Operating Margin(%) | 10.6% | 8.6% | 10.4% | 6.8% | 14.2% | ||||||||
West Vantage Research and Development Expense($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
West Vantage Selling, General and Administrative Expense($M) | 8.10 | 8.30 | 7.80 | 7.80 | 7.50 | 7 | 7.60 | 7.10 | 6.70 | 6.20 | 6.20 | ||
West Vantage Other Segment Expense (Income), Net($M) | 0.40 | 0 | -0.10 | 0.60 | 0.50 | 0.80 | 0.60 | -0.40 | 0.50 | -0.40 | -0.20 | ||
West Vantage Depreciation and Amortization($M) | 7.50 | 9.20 | 8 | 7.60 | 7.10 | 6.80 | 6.40 | 6.20 | 5.50 | 4.90 | 4.70 | ||
West Vantage Capital Expenditures($M) | 8.20 | 5.10 | 5.60 | 18.3 | 13.6 | 25.5 | 18.1 | 24.2 | 30 | 39.2 | 27.6 | ||
Total Reportable Segment Operating Profit($M)8 | 246 | 225 | 205 | 200 | 198 | 180 | 144 | 179 | 180 | 148 | 143 | 182 | |
Corporate General and Unallocated Administrative Costs($M) | 20.3 | 16.5 | 17.2 | 20.8 | 19 | 16.8 | 17.8 | 11.4 | 14.3 | 17.5 | 15.4 | ||
Corporate Stock-Based Compensation Expense($M) | 4.30 | 10.9 | 6.60 | 6.70 | 8.40 | 7.40 | 1.30 | 4.30 | 5.10 | 4.30 | 5 | ||
Corporate Amortization of Acquisition-Related Intangible Assets($M) | 0 | 0 | 0 | 0 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | ||||
Corporate Restructuring, Severance and Related Charges($M) | 6.30 | 1.50 | 1.40 | 1.40 | 2.50 | 1.60 | 17.8 | 3 | -0.90 | 0 | 0 | ||
Corporate Portfolio Divestiture and M&A Net Loss (Gain)($M) | -54 | 6.40 | 1.90 | 0 | 0 | 0 | |||||||
Other Unallocated Corporate Operating Items($M) | -45.9 | 18.3 | 3.90 | 15.4 | 2.50 | 1.60 | 18 | 3.20 | -0.70 | 0.20 | 0.20 | -1 | |
Corporate Capital Expenditures($M) | 2.30 | 2.70 | 0.60 | 1.60 | 2 | 1.20 | 1.30 | 1.60 | 3.50 | 2.50 | 1.90 | ||
Corporate Depreciation and Amortization($M) | 0.80 | 0.70 | 0.80 | 0.70 | 0.80 | 0.90 | 0.90 | 1 | 0.90 | 1 | 0.90 | ||
Consolidated Adjusted Operating Profit (Non-GAAP)($M)5 | 222 | 197 | 181 | 172 | 170 | 155 | 125 | 163 | 161 | 126 | 123 | 160 | |
Consolidated Adjusted Operating Profit Margin (Non-GAAP)(%) | 25.3% | 22.6% | 21.4% | 21.4% | 21.1% | 20.3% | 17.9% | 21.7% | 21.5% | 18.0% | 17.7% | 21.8% | |
Consolidated Adjusted Net Income (Non-GAAP)($M) | 189 | 169 | 154 | 148 | 142 | 134 | 106 | 133 | 136 | 112 | 116 | 137 | |
Consolidated Adjusted Diluted Earnings Per Share (Non-GAAP)($) | 2.66 | 2.37 | 2.13 | 2.04 | 1.96 | 1.84 | 1.45 | 1.82 | 1.85 | 1.52 | 1.56 | 1.83 | |
Consolidated GAAP Gross Margin(%) | 39.7% | 37.7% | 35.1% | 37.8% | 36.6% | 35.7% | 33.2% | 36.5% | 35.4% | 32.8% | 33.1% | 38.0% | |
Consolidated GAAP Operating Margin(%) | 30.6% | 20.5% | 21.0% | 19.5% | 20.8% | 20.1% | 15.3% | 21.3% | 21.6% | 18.0% | 17.7% | 22.0% | |
Remaining Performance Obligations (Backlog) Expected Within 1 Year($M)1 | 40.1 | 42.1 | 58.4 | 43 | 43.4 | 44.7 | |||||||
Remaining Performance Obligations (Backlog) Expected Beyond 1 Year($M) | 3.60 | 3.60 | 3.80 | 4.30 | 2.80 | 3.10 | |||||||
Contract Liabilities (Customer Advances & Deferred Revenue)($M)2 | 43.7 | 45.7 | 62.2 | 47.3 | 46.2 | 47.8 | 53.8 | 52.2 | 57.9 | ||||
Contract Assets (Unbilled Revenue)($M) | 15.1 | 17.2 | 15.4 | 27.5 | 27.9 | 25.8 | 42.3 | 22.6 | 19.9 | ||||
Prior-Year Contract Liabilities Recognized as Revenue($M) | 23.1 | 18.3 | 15.5 | ||||||||||
Total Inventories($M)3 | 465 | 447 | 453 | 438 | 421 | 389 | 401 | 419 | 430 | ||||
Inventories: Raw Materials($M) | 170 | 179 | 173 | 183 | 174 | 163 | 170 | 174 | 174 | ||||
Inventories: Work in Process($M) | 95.4 | 93.8 | 109 | 97.6 | 91.1 | 82.9 | 80 | 81.1 | 81.6 | ||||
Inventories: Finished Goods($M) | 199 | 175 | 171 | 157 | 156 | 143 | 151 | 164 | 174 | ||||
Property, Plant and Equipment, Gross($M)2 | 3,266 | 3,249 | 3,223 | 3,233 | 3,178 | 3,005 | 2,991 | 2,864 | 2,791 | ||||
PP&E: Accumulated Depreciation($M) | 1,594 | 1,562 | 1,521 | 1,492 | 1,456 | 1,374 | 1,420 | 1,370 | 1,343 | ||||
Property, Plant and Equipment, Net($M) | 1,672 | 1,686 | 1,702 | 1,741 | 1,722 | 1,632 | 1,571 | 1,494 | 1,449 | ||||
Total Lease Cost($M)5 | 12 | 11.9 | 11.2 | 9.50 | 11.3 | 10.5 | 10.6 | 9.70 | 10.1 | 8.90 | 8 | 8.10 | |
Operating Lease Cost($M) | 8 | 7.30 | 7.20 | 6.20 | 6.90 | 6.80 | 6.60 | 6.10 | 6.40 | 6.10 | 5.60 | 5.30 | |
Variable Lease Cost($M) | 2.30 | 3 | 2.50 | 1.80 | 2.90 | 2.50 | 2.90 | 2.70 | 2.50 | 1.90 | 1.90 | 1.10 | |
Short-Term Lease Cost($M) | 1.20 | 1.10 | 0.90 | 1 | 1 | 0.70 | 0.80 | 0.60 | 0.80 | 0.60 | 0.50 | 1.70 | |
Operating Leases: Weighted-Average Remaining Lease Term(năm) | 8.2 | 8.3 | 8.3 | 6.1 | 6.2 | 7.9 | 8.5 | 8.6 | 9.4 | ||||
Operating Leases: Weighted-Average Discount Rate(%) | 4.8% | 4.7% | 4.7% | 4.0% | 4.0% | 4.1% | 3.8% | 4.0% | 3.6% | ||||
Common Shares Repurchased Under Share Repurchase Programs2 | 663,511 | 538,591 | 1,222,019 | 0 | 0 | 2,312 | 550,281 | 173,246 | 170,771 | 509,336 | 729,679 | 512,262 | |
Total Cost of Shares Repurchased($M) | 231 | 157 | 298 | 0 | 0.50 | 134 | 54.4 | 52.4 | 187 | 267 | 177 | ||
Average Price Paid per Share Repurchased($) | 348 | 244 | 223 | 243 | 306 | 367 | 366 | 346 | |||||
Carrying Value of Investments in Affiliated Companies($M)2 | 216 | 208 | 209 | 221 | 225 | 212 | 218 | 198 | 203 | ||||
Equity-Method Investments Carrying Value (Primarily Daikyo Seiko, Ltd.)($M) | 215 | 207 | 205 | 214 | 217 | 205 | 210 | ||||||
Non-Marketable Cost-Method Investments Carrying Value($M) | 0.60 | 0.60 | 4.10 | 7.30 | 7.30 | 7.20 | 7.20 | ||||||
Equity in Net Income of Affiliated Companies (Daikyo Seiko & Mexico Affiliates)($M) | 4.30 | 6.10 | 3.40 | 3.90 | 2.10 | 5 | 3.40 | 2 | 3.90 | 4.50 | 4.30 | 3.30 | |
Related-Party Inventory & Component Purchases from Daikyo Seiko / Affiliates($M)1 | 38 | 34.3 | 34 | 39.5 | 25.2 | 30.2 | 27.7 | 26.4 | 30.1 | 24.9 | 28.6 | 24 | |
Payables Due to Daikyo Seiko / Affiliated Companies($M) | 34.2 | 27.2 | 27.5 | 19.8 | 24.8 | 25.6 | 24.8 | 20.4 | 26.7 | ||||
Related-Party Sales to Daikyo Seiko / Affiliates($M)1 | 5.90 | 4.50 | 3.20 | 3.30 | 3.40 | 2.80 | 3.20 | 4.60 | 3.50 | 4 | 3.20 | 2.70 | |
Receivables Due from Daikyo Seiko / Affiliated Companies($M) | 3.60 | 2.70 | 2.30 | 1.20 | 2.20 | 2.20 | 2.70 | 2.40 | 2.10 | ||||
West & Medimop U.S. FDA 510(k) Premarket Device Clearances3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
West U.S. FDA Premarket Approvals (PMA) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
West U.S. FDA Medical Device Recalls | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
West U.S. FDA Device Enforcement Actions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
West U.S. FDA MAUDE Medical Device Adverse Event Reports3 | 2 | 3 | 2 | 0 | 2 | 2 | 0 | 0 | 3 | 1 | 0 | 0 | |
MAUDE Reports: Device Malfunction | 2 | 3 | 2 | 0 | 2 | 2 | 0 | 0 | 3 | 1 | 0 | 0 | |
MAUDE Reports: Patient Injury | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
MAUDE Reports: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
U.S. MedTech Industry Total FDA 510(k) Clearances2 | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
U.S. MedTech Industry Total FDA PMA Approvals | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
U.S. MedTech Industry Total FDA MAUDE Adverse Event Reports | 1,189,467 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
Cumulative ClinicalTrials.gov Studies Citing West / Daikyo / SmartDose / Crystal Zenith1 | |||||||||||||
New ClinicalTrials.gov Studies Started | 3 | 1 | 1 | 2 | 1 | 2 | |||||||
U.S. PPI: Surgical and Medical Instrument Manufacturing (Index 1982=100)1 | |||||||||||||
U.S. Census Quarterly Hospital Taxable Revenue($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Consolidated Revenue (Income Statement)($M)16 | 875 | 872 | 845 | 805 | 805 | 767 | 698 | 749 | 747 | 702 | 695 | 732 | |
Total Assets (Balance Sheet)($M)29 | 4,061 | 4,076 | 4,110 | 4,270 | 4,106 | 3,953 | 3,618 | 3,643 | 3,675 | 3,489 | 3,602 | 3,830 | |
Operating Cash Flow (Cash Flow Statement)($M)10 | 190 | 124 | 89.9 | 251 | 197 | 177 | 129 | 190 | 180 | 165 | 118 | 239 | |
Proprietary Products Segment Revenue (Historical Financial Statement Series)($M)1 | 729 | 723 | 694 | 662 | 648 | 620 | 563 | 614 | 601 | 560 | 560 | 594 | |
West Vantage / Contract-Manufactured Products Segment Revenue (Historical Financial Statement Series)($M)1 | 146 | 150 | 151 | 143 | 157 | 147 | 135 | 135 | 146 | 142 | 136 | 138 | |
7 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Revenue & Operational Drivers (Groups 1–4): Decomposes West Pharmaceutical Services' revenue and operating performance across Proprietary Products (High-Value Product Components, HVP Delivery Devices, and Standard Packaging) and West Vantage (formerly Contract-Manufactured Products), by Market Unit (Biologics, Pharma, Generics), by Region and Country (Americas, EMEA, Asia Pacific; U.S., Germany, France, Ireland), plus GLP-1 revenue shares (total, elastomers, and contract manufacturing), EU GMP Annex 1 upgrade project counts, and ASU 2023-07 segment cost breakdowns (COGS, R&D, SG&A, D&A, CapEx).
- Consolidated vs. Parent-Only / Subsidiary Assessment: West Pharmaceutical Services, Inc. files consolidated financial statements under U.S. GAAP (Form 10-K/10-Q) and does not file standalone parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Operations of West's 49%-owned Japanese affiliate Daikyo Seiko, Ltd. are captured directly from Note 6 disclosures in Group 6 (ownership stake, investment carrying value, equity in net income, and related-party purchases, sales, payables, and receivables).
- Derived Period Splits: Where SEC filings report cumulative year-to-date (6M, 9M, or 12M FY) figures for quarterly flow items (such as Q4 income statement, segment, related-party, and cash flow figures), standalone quarters are derived strictly via Q2 = 6M − Q1, Q3 = 9M − 6M, and Q4 = full year − first nine months (FY − 9M).
Không hiện vì thiếu các kỳ gần đây (6)
- Annual Packaging Components Manufactured (>40 billion / >41 billion / ~43 billion / ~45 billion units per year) — Disclosed only as approximate bounds ('more than 40 billion', 'over 41 billion') in Form 10-K and Corporate Sustainability Reports; excluded because bound approximations are not permitted.
- Customer Drug Approvals Supported (% of FDA/EMA biologics and small-molecule approvals) — Disclosed only as marketing bounds ('more than 90%', 'nearly 100%') in investor presentations; excluded because bound approximations are not permitted.
- Physical Production Capacity & Utilization by Manufacturing Plant (25 global sites) — West discloses total cleanroom/building square footage only at an aggregate narrative level and does not publish plant-level unit capacity or utilization rates.
- Daikyo Seiko, Ltd. Full Standalone Financial Statements — Daikyo Seiko is a privately held Japanese company (49% owned by West); West discloses its equity-method income, carrying value, and related-party purchases/sales/balances in Note 6, but does not file separate standalone financial statements for Daikyo under Rule 3-09.
- Employee Function Share by Segment (Proprietary Products 73%, Contract-Manufactured Products 17%) — Introduced for the first time in the FY2025 Form 10-K with only 1 annual period available; excluded until a second annual period is reported.
- Country-Specific Gender Pay Gap Reports (Ireland & Brazil) — Only 1–2 standalone annual PDF snapshots published without a continuous multi-year table across all periods.
Dữ liệu cập nhật 2026-11-09.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Core Revenue Drivers — Product Categories, GLP-1 Franchise & EU GMP Annex 1
Proprietary Products by Market Unit (Biologics, Pharma, Generics) & Customer Concentration
Geographic Revenue, Country-Level Operations & Tax Jurisdiction Pre-Tax Income
- Americas Net Sales ($M)9 kỳ
- Europe, Middle East & Africa (EMEA) Net Sales ($M)9 kỳ
- Asia Pacific Net Sales ($M)9 kỳ
- United States Net Sales ($M)17 kỳ
- Germany Net Sales ($M)17 kỳ
- France Net Sales ($M)17 kỳ
- Ireland Net Sales ($M)9 kỳ
- Other European Countries Net Sales ($M)17 kỳ
- Other Countries Net Sales ($M)17 kỳ
- U.S. Domestic Income Before Income Taxes ($M)10 kỳ
- Foreign Income Before Income Taxes ($M)10 kỳ
Segment Profitability, ASU 2023-07 Cost Structure & Non-GAAP Performance
- Proprietary Products Segment Gross Profit ($M)35 kỳ
- Proprietary Products Segment Operating Profit ($M)35 kỳ
- West Vantage Segment Gross Profit ($M)35 kỳ
- West Vantage Segment Operating Profit ($M)35 kỳ
- Total Reportable Segment Operating Profit ($M)27 kỳ
- Consolidated Adjusted Operating Profit (Non-GAAP) ($M)35 kỳ
Order Backlog (RPO), Contract Balances, Inventory Stages, Tooling & Share Repurchases
- Remaining Performance Obligations (Backlog) Expected Within 1 Year ($M)6 kỳ
- Contract Liabilities (Customer Advances & Deferred Revenue) ($M)23 kỳ
- Total Inventories ($M)22 kỳ
- Property, Plant and Equipment, Gross ($M)22 kỳ
- Finite-Lived Intangible Assets, Net ($M)9 kỳ
- Total Lease Cost ($M)32 kỳ
- Common Shares Repurchased Under Share Repurchase Programs28 kỳ
Affiliate Operations — Daikyo Seiko, Ltd. (49%-Owned Equity Affiliate)
- West Equity Ownership Stake in Daikyo Seiko, Ltd. (Japan) (%)8 kỳ
- Carrying Value of Investments in Affiliated Companies ($M)22 kỳ
- Equity in Net Income of Affiliated Companies (Daikyo Seiko & Mexico Affiliates) ($M)32 kỳ
- Related-Party Inventory & Component Purchases from Daikyo Seiko / Affiliates ($M)18 kỳ
- Related-Party Sales to Daikyo Seiko / Affiliates ($M)18 kỳ
Workforce, Human Capital, Occupational Safety & 3TG Supply Chain Compliance
Environmental Sustainability (GHG, Energy, Water, Waste) & Corporate Philanthropy
External Regulatory Clearances (openFDA), Clinical Trials & Industry Benchmarks (FRED)
- West & Medimop U.S. FDA 510(k) Premarket Device Clearances154 kỳ
- West U.S. FDA MAUDE Medical Device Adverse Event Reports154 kỳ
- U.S. MedTech Industry Total FDA 510(k) Clearances154 kỳ
- Cumulative ClinicalTrials.gov Studies Citing West / Daikyo / SmartDose / Crystal Zenith10 kỳ
- U.S. PPI: Surgical and Medical Instrument Manufacturing (Index 1982=100) (×)129 kỳ
Consolidated Financial Statements (Income Statement, Balance Sheet & Cash Flows)
Historical Segment Financial Statement Series
- Proprietary Products Segment Revenue (Historical Financial Statement Series) ($M)19 kỳ
- West Vantage / Contract-Manufactured Products Segment Revenue (Historical Financial Statement Series) ($M)18 kỳ
- Legacy Packaging Systems Segment Revenue (Pre-2016 Segment Structure) ($M)40 kỳ
- Legacy Delivery Systems Segment Revenue (Pre-2016 Segment Structure) ($M)44 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của West Pharmaceutical Services
- West Form 10-Q (FY2026Q3, filed 2026-10-29) ↗
- West Form 8-K (FY2026Q3, filed 2026-10-29) ↗
- West Form 8-K (FY2025Q4, filed 2026-02-12) ↗
- West Form 10-K (FY2025, filed 2026-02-17) ↗
- West Form 10-K (filed 2026-02-17) ↗
- U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
- West 2025 Corporate Sustainability Report ↗
- West Form 10-Q (filed 2026-10-29) ↗
- West Form 10-Q (filed 2023-10-26) ↗
- West Form 10-K (filed 2016-02-26) ↗
- West Form 8-K (FY2026Q3, filed 2026-10-29) ↗
- West Form 8-K (FY2025Q4, filed 2026-02-12) ↗
See a number that looks wrong?